Logo of jcinvestThe Journal of Clinical Investigation
J Clin Invest. 1979 Jul; 64(1): 117–128.
PMCID: PMC372097
PMID: 447848

Inhibition of intrapituitary thyroxine to 3.5.3'-triiodothyronine conversion prevents the acute suppression of thyrotropin release by thyroxine in hypothyroid rats.

P R Larsen, T E Dick, B P Markovitz, M M Kaplan, and T G Gard
Copyright and License information ► Disclaimer

Abstract

Iopanoic acid has been shown to block thyroxine (T4)-5'-monodeiodination in rat anterior pituitary in vitro. To test the hypothesis that the acute decrease in thyrotropin (TSH) after infusion of T4 into hypothyroid rats requires intrapituitary T4 to 3,5,3'-triiodothyroxine (T3) conversion, the effect of iopanoic acid treatment on the generation of nuclear T3 from intrapituitary conversion and the response to TSH were compared in control and iopanoic acid-treated animals. 5 mg/100 g body weight iopanoic acid given 24, 16, and 1.5 h before administration of 125I-T4 reduced the quantity of pituitary nuclear 125I-T3 from local (intrapituitary) T4 to T3 conversion by 60-100%. In association with inhibition of intrapituitary T4 to T3 conversion, there was an increase in the binding of 125I-T4 to the nuclear receptor of the pituitary but the total iodothyronine content of the nuclei was still less than half of the nuclear iodothyronine in control animals. Iopanoic acid did not affect the nuclear/plasma ratio of injected 131I-T3 in the same animals, but did appear to impair 131I-T3 clearance or reduce its distribution volume. Treatment with iopanoic acid did not reduce the quantity of nuclear 125I-T3 in the liver, kidney, or heart of the same animals more than expected from the changes in serum 125I-T3. In control hypo-thyroid animals pretreated with iopanoic acid, the mean TSH was not significantly decreased from the initial value by T4 injection. Iopanoic acid pretreatment did not interfere with the acute TSH response of chronically hypothyroid rats to 70 ng of T3/100 g body weight. These results establish that intrapituitary generations of T3 from T4 is required for the acute decrease in TSH which occurs after T4 infusion. The data also are consistent with the content that it is nuclear binding of the T3 generated from T4 which initiates the inhibition of TSH release.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.6M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
icon of scanned page 117
117
icon of scanned page 118
118
icon of scanned page 119
119
icon of scanned page 120
120
icon of scanned page 121
121
icon of scanned page 122
122
icon of scanned page 123
123
icon of scanned page 124
124
icon of scanned page 125
125
icon of scanned page 126
126
icon of scanned page 127
127
icon of scanned page 128
128
 

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Silva JE, Larsen PR. Pituitary nuclear 3,5,3'-triiodothyronine and thyrotropin secretion: an explanation for the effect of thyroxine. Science. 1977 Nov 11;198(4317):617–620. [PubMed]
  • Silva JE, Larsen PR. Contributions of plasma triiodothyronine and local thyroxine monodeiodination to triiodothyronine to nuclear triiodothyronine receptor saturation in pituitary, liver, and kidney of hypothyroid rats. Further evidence relating saturation of pituitary nuclear triiodothyronine receptors and the acute inhibition of thyroid-stimulating hormone release. J Clin Invest. 1978 May;61(5):1247–1259. [PMC free article] [PubMed]
  • Oppenheimer JH, Schwartz HL, Surks MI. Propylthiouracil inhibits the conversion of L-thyroxine to L-triiodothyronine. An explanation of the antithyroxine effect of propylthiouracil and evidence supporting the concept that triiodothyronine is the active thyroid hormone. J Clin Invest. 1972 Sep;51(9):2493–2497. [PMC free article] [PubMed]
  • Frumess RD, Larsen PR. Correlation of serum triiodothyronine (T3) and thyroxine (T4) with biologic effects of thyroid hormone replacement in propylthiouracil-treated rats. Metabolism. 1975 Apr;24(4):547–554. [PubMed]
  • Bürgi H, Wimpfheimer C, Burger A, Zaunbauer W, Rösler H, Lemarchand-Béraud T. Changes of circulating thyroxine, triiodothyronine and reverse triiodothyronine after radiographic contrast agents. J Clin Endocrinol Metab. 1976 Dec;43(6):1203–1210. [PubMed]
  • Wu SY, Chopra IJ, Solomon DH, Bennett LR. Changes in circulating iodothyronines in euthyroid and hyperthyroid subjects given ipodate (Oragrafin), an agent for oral cholecystography. J Clin Endocrinol Metab. 1978 Apr;46(4):691–697. [PubMed]
  • Kaplan MM, Utiger RD. Iodothyronine metabolism in rat liver homogenates. J Clin Invest. 1978 Feb;61(2):459–471. [PMC free article] [PubMed]
  • Silva JE, Kaplan MM, Cheron RG, Dick TE, Larsen PR. Thyroxine to 3,5,3'-triiodothyronine conversion by rat anterior pituitary and liver. Metabolism. 1978 Nov;27(11):1601–1607. [PubMed]
  • Weeke J, Orskov H. Synthesis of 125I monolabelled 3, 5, 3'-triiodothyronine and thyroxine of maximum specific activity for radioimmunoassay. Scand J Clin Lab Invest. 1973 Dec;32(4):357–360. [PubMed]
  • Silva JE, Dick TE, Larsen PR. The contribution of local tissue thyroxine monodeiodination to the nuclear 3,5,3'-triiodothyronine in pituitary, liver, and kidney of euthyroid rats. Endocrinology. 1978 Oct;103(4):1196–1207. [PubMed]
  • Zimmerman CJ, Izumi M, Larsen PR. Isolation of labeled triiodothyronine from serum using affinity chromatography: application to the extimation of the peripheral T4 to T3 conversion in rats. Metabolism. 1978 Mar;27(3):303–313. [PubMed]
  • Silva JE, Larsen PR. Peripheral metabolism of homologous thyrotropin in euthyroid and hypothyroid rats: acute effects of thyrotropin-releasing hormone, triiodothyronine, and thyroxine. Endocrinology. 1978 Jun;102(6):1783–1796. [PubMed]
  • MATTHEWS CM. The theory of tracer experiments with 131I-labelled plasma proteins. Phys Med Biol. 1957 Jul;2(1):36–53. [PubMed]
  • PEARSON JD, VEALL N, VETTER H. A practical method for plasma albumin turnover studies. Strahlentherapie. 1958;107(SONDERBD):290–297. [PubMed]
  • Oppenheimer JH, Schwartz HL, Koerner D, Surks MI. Limited binding capacity sites for L-triiodothyronine in rat liver nuclei. Nuclear-cytoplasmic interrelation, binding constants, and cross-reactivity with L-thyroxine. J Clin Invest. 1974 Mar;53(3):768–777. [PMC free article] [PubMed]
  • Larsen PR, Frumess RD. Comparison of the biological effects of thyroxine and triiodothyronine in the rat. Endocrinology. 1977 Apr;100(4):980–988. [PubMed]
  • JAGIELLO GM, McKENZIE JM. Influence of propylthiouracil on the thyroxine-thyrotropin interplay. Endocrinology. 1960 Oct;67:451–456. [PubMed]
  • JONES SL, VAN MIDDLESWORTH L. Normal I-131 L-thyroxine metabolism in the presence of potassium perchlorate and interrupted by propylthiouracil. Endocrinology. 1960 Dec;67:855–861. [PubMed]
  • Oppenheimer JH, Schwartz HL, Surks MI. Tissue differences in the concentration of triiodothyronine nuclear binding sites in the rat: liver, kidney, pituitary, heart, brain, spleen, and testis. Endocrinology. 1974 Sep;95(3):897–903. [PubMed]
  • Kaplan MM, Utiger RD. Iodothyronine metabolism in liver and kidney homogenates from hyperthyroid and hypothyroid rats. Endocrinology. 1978 Jul;103(1):156–161. [PubMed]
  • Balsam A, Sexton F, Ingbar SH. The effect of thyroidectomy, hypophysectomy, and hormone replacement on the formation of triiodothyronine from thyroxine in rat liver and kidney. Endocrinology. 1978 Nov;103(5):1759–1767. [PubMed]
  • Harris AR, Fang SL, Vagenakis AG, Braverman LE. Effect of starvation, nutriment replacement, and hypothyroidism on in vitro hepatic T4 to T3 conversion in the rat. Metabolism. 1978 Nov;27(11):1680–1690. [PubMed]
  • Oppenheimer JH, Schwartz HL, Surks MI, Koerner D, Dillmann WH. Nuclear receptors and the initiation of thyroid hormone action. Recent Prog Horm Res. 1976;32:529–565. [PubMed]
Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation